Leading Articles

Procalcitonin and Other Biomarkers for the Assessment of Disease Severity and Guidance of Treatment in Bacterial Infections  PDF    

Philipp Schuetz, MD1, Mirjam Christ-Crain, MD1, Beat Müller, MD1,2

The ambiguities of clinical signs and the limitations of current microbial techniques for the diagnosis of bacterial infections – and to grade their severity – are well known... Read More >>

The Diagnostic and Therapeutic Approach to Fungal Infections in Critical Care Settings  PDF    

Rafael Zaragoza1 and Javier Pemán2

Invasive fungal infections, especially in the critical care setting, have become an excellent target for prophylactic, empiric, and preemptive therapy interventions due to their associated high morbidity, mortality rate, increased incidence, and healthcare costs... Read More >>

Selenium in Early Sepsis: A Marker for Change?  PDF    

W Graham Carlos, MD, Curtis Ramsey MS, and Joseph Fraiz, MD

Sepsis is the leading cause of mortality in the critically ill... Read More >>




Clinical Reviews
Case Studies Commentary and analysis on recent key papers

Meeting Reports

Report from the 20th Annual Congress of the European Society of Intensive Care Medicine (ESICM)  PDF    

Marc Leone, MD, PhD

Berlin, Germany, hosted the 20th congress of the European Society of Intensive Care Medicine (ESICM) at the International Conference Center from October 7–10, 2007... Read More >>



SMART
In this month's SMART:
  • Crucial Presentations from the Scandinavian Society of Anaesthesiology and Intensive Care Medicine.
  • Research and treatment in pediatric sepsis.
  • Key papers and news from the world media.
Enter SMART >> SMART

SMARTbot
Activate your personal SMARTbot today! You choose how SMARTbot will search PubMed. SMARTbot will report back (you decide how often) with the results from your customised searches
Activate your personal SMARTbot today! >> SMARTbot
SMARTbot
The material published in Advances in Sepsis is FREE from copyright restriction when used for non-commercial educational purposes.
More information
SMARTbot



Advances in Sepsis, SMART™, and SMARTbot™ are supported by educational grants from Eli Lilly and Company, Acute Care. Certain authors and editors may have financial or other relationships with Eli Lilly and Company. Some of the information/data reported here for drugs/devices discussed may differ from information/data contained in the prescribing information approved by regulatory authorities in specific countries. For approved information and uses for drugs/devices discussed, please consult the manufacturer's prescribing information.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of ACCME through the joint sponsorship of the University of Kentucky College of Medicine and Remedica. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians. The University of Kentucky is an equal opportunity university.